TABLE 1.
Included studies of single-dose aminoglycoside therapy for urinary tract infectiona
| Reference | Setting | Population |
UTI details |
Aminoglycoside regimen (name [dose])c | Efficacy (no. [%]) |
Safetyf |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age group | Subject/sex distributionb | No. (%) with urinary malformation | Upper or Lower | Initial or Recurrent | Microbiologic cure | Clinical cure | Relapse | Recurrenced | Sustained microbiologic curee | No. (%) of ADE | No. of ADE type | |||
| Varese et al. (11) | Inpatient | Children | 24 F/8 M | 10 (31) | NR | Mixed | Gentamicin (5 mg/kg) | 31 (97) | NR | 2 (6) | 6 (19) | 25 (78) | 0 | |
| Vigano et al. (12) | Inpatient | Children | 25 F/5 M | 12 (40) | Lower | Mixed | Netilmicin (4.5 mg/kg) | 29 (97) | NR | 2 (7) | 4 (13) | 25 (83) | 0 | |
| Varese (13) | Mixed | Children | 23 F/12 M | 7 (20) | NR | NR | Netilmicin (5 mg/kg) | 35 (100) | NR | 1 (3) | 5 (14) | 30 (86) | 0 | |
| Fairley et al. (14) | Outpatient | NR | 35 F/2 M | 16 (43) | Mixed | Recurrent | Kanamycin (500 mg) | 37 (89) | NR | 11 (30) | 16 (43) | NA | 0 | |
| Bailey et al. (15) | Outpatient | Adults | 22 F | 0 | Lower | NR | Netilmicin (150 mg) | 22 (95) | NR | 0 | 0 | NA | 0 | |
| Rocca Rossetti (16) | Outpatient | Mixed | 13,258 NR | 0 | Lower | NR | Amikacin (adults, 500 mg; children, 7.5 mg/kg) | NR | 10,983 (83) | NR | NR | NA | 60 (0.5) | 7 NT, 53 VT |
| Caramalli et al. (17) | Inpatient | Adults | 38 F/38 M | NR | NR | Mixed | Amikacin (15 mg/kg), netilmicin (5 mg/kg) | 73 (96) | 72 (95) | NR | 25 (33) | 48 (63) | 0 | |
| Principi et al. (18) | Mixed | Children | 40 F/24 M | 10 (16) | Lower | Mixed | Netilmicin (5 mg/kg) | 62 (97) | NR | NR | 10 (16) | 52 (81) | 3 (5) | 3 ISP |
| Prát et al. (19) | Outpatient | Adults | 36 F/8 M | 21 (48) | NR | Mixed | Netilmicin (300 mg) | 39 (89) | NR | NR | 14 (32) | NA | 1 (2) | 1 PAR |
| Grimwood et al. (20) | Mixed | Children | 29 F/10 M | 26 (67) | Mixed | Mixed | Gentamicin (3 mg/kg) | 34 (87) | NR | 5 (13) | 7 (18) | 27 (69) | 0 | |
| Khan et al. (21) | Outpatient | Children | 21 F | 0 | Lower | Recurrent | Gentamicin (5 mg/kg, maximum 300 mg) | 21 (100) | NR | 0 | 9 (43) | 12 (57) | 0 | |
| Wallen et al. (22) | Outpatient | Children | 26 F | 0 | Lower | Initial | Amikacin (7.5 mg/kg, maximum 240 mg) | 24 (92) | NR | 4 (15) | 6 (23) | 18 (69) | 0 | |
| Krzeska (23) | Outpatient | Children | 92 F/28 M | NR | NR | Mixed | Amikacin (10 mg/kg) | NR | NR | NR | 12 (10)g | NA | 0 | |
a
NR, not reported.
b
Numbers represent number of females (F) and males (M) or number of isolates.
c
All doses administered intramuscularly.
dRelapses plus reinfections.
eFor studies with minimum 30 days follow-up. NA, not applicable.
fADE, adverse drug event; NT, nephrotoxicity; VT, vestibular toxicity; ISP, injection site pain; PAR, paresthesia.
gWithin 3 years.